- A novel intestinal-restricted FXR agonist
-
In this study, a new intestinal-restricted FXR agonist named fexaramine-3 (Fex-3) was developed and investigated both in vitro and in vivo. Fex-3 could selectively activate intestinal FXR and promote the expression of BSEP and SHP while suppressing CYP7A1 which is involved in bile acids syntheses better than the reported intestinal-restricted FXR agonist fexaramine (Fex). We demonstrated that Fex-3 targeted on FXR in ileum and has better selectivity than Fex. And the study of utilizing Fex-3 to reduce obesity was undergoing.
- Wang, Hong,Zhao, Zhou,Zhou, Jiyu,Guo, Yitong,Wang, Guangji,Hao, Haiping,Xu, Xiaowei
-
-
Read Online
- Simple and efficient synthesis of belinostat
-
A novel synthesis of belinostat (1) starting from 3-nitrobenzaldehyde has been developed. The key step in this sequence involves the conversion of (2E)-3-(3-aminophenyl)acrylic acid methyl ester to (2E)-3-(3- chlorosulfonylphenyl)acrylic acid methyl ester via diazotization and sulfonylation. Taylor & Francis Group, LLC.
- Yang, Lei,Xue, Xiaowen,Zhang, Yihua
-
-
Read Online
- 4-Acyl Pyrrole Capped HDAC Inhibitors: A New Scaffold for Hybrid Inhibitors of BET Proteins and Histone Deacetylases as Antileukemia Drug Leads
-
Multitarget drugs are an emerging alternative to combination therapies. In three iterative cycles of design, synthesis, and biological evaluation, we developed a novel type of potent hybrid inhibitors of bromodomain, and extra-terminal (BET) proteins and histone deacetylases (HDACs) based on the BET inhibitor XD14 and well-established HDAC inhibitors. The most promising new hybrids, 49 and 61, displayed submicromolar inhibitory activity against HDAC1-3 and 6, and BRD4(1), and possess potent antileukemia activity. 49 induced apoptosis more effectively than the combination of ricolinostat and birabresib (1:1). The most balanced dual inhibitor, 61, induced significantly more apoptosis than the related control compounds 62 (no BRD4(1) affinity) and 63 (no HDAC inhibition) as well as the 1:1 combination of both. Additionally, 61 was well tolerated in an in vivo zebrafish toxicity model. Overall, our data suggest an advantage of dual HDAC/BET inhibitors over the combination of two single targeted compounds.
- Ahlert, Heinz,Bhatia, Sanil,Borkhardt, Arndt,Breit, Bernhard,Gunther, Stefan,Hansen, Finn K.,Hugle, Martin,Kraft, Fabian B.,Mishra, Pankaj,Schaker-Hubner, Linda,Schliehe-Diecks, Julian,Scholer, Andrea,Warstat, Robin
-
p. 14620 - 14646
(2021/10/20)
-
- Synthesis of 2-(N-cyclicamino)quinoline combined with methyl (E)-3-(2/3/4-aminophenyl)acrylates as potential antiparasitic agents
-
A rationally designed series of 2-(N-cyclicamino)quinolines coupled with methyl (E)-3-(2/3/4-aminophenyl)acrylates was synthesized and subjected to in vitro screening bioassays for potential antiplasmodial and antitrypanosomal activities against a chloroquine-sensitive (3D7) strain of Plasmodium falciparum and nagana Trypanosoma brucei brucei 427, respectively. Substituent effects on activity were evaluated; meta-acrylate 24 and the ortho-acrylate 29 exhibited the highest antiplasmodial (IC50 = 1.4 μM) and antitrypanosomal (IC50 = 10.4 μM) activities, respectively. The activity against HeLa cells showed that the synthesized analogs are not cytotoxic at the maximum tested concentration. The ADME (absorption, distribution, metabolism, and excretion) drug-like properties of the synthesized compounds were predicted through the SwissADME software.
- Bokosi, Fostino R. B.,Beteck, Richard M.,Laming, Dustin,Hoppe, Heinrich C.,Tshiwawa, Tendamudzimu,Khanye, Setshaba D.
-
-
- SUBSTITUTED AMIDE COMPOUNDS USEFUL AS FARNESOID X RECEPTOR MODULATORS
-
Disclosed are compounds of Formula (I): or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt or solvate thereof, wherein Q is: (i) halo, cyano, hydroxyl, NRxRx, C(O)OH, C(O)NH2, C1-6 alkyl substituted with zero to 6 R1a, or P(O)R1cR1c; or (ii) L R1; and A, X1, X2, X3, X4, Z1, Z2, R1, R1a, R1c, R2, R3a, R3b, Rx, L, a, b, and d are defined herein. Also disclosed are methods of using these compounds to modulate the activity of farnesoid X receptor (FXR); pharmaceutical compositions comprising these compounds; and methods of treating a disease, disorder, or condition associated with FXR dysregulation, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.
- -
-
Page/Page column 178; 179; 180
(2020/08/28)
-
- SUBSTITUTED AMIDE COMPOUNDS USEFUL AS FARNESOID X RECEPTOR MODULATORS
-
Disclosed are compounds of Formula (I) or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt or solvate thereof, wherein Q is a 5-membered heterocyclyl or 5-membered heteroaryl having 1 to 4 heteroatoms independently selected from N, O, and S, substituted with zero to 4 R1; and A, X1, X2, X3, X4, Z1, Z2, R1, R2, R3a, R3b, a, b, and d are defined herein. Also disclosed are methods of using these compounds to modulate the activity of farnesoid X receptor (FXR); pharmaceutical compositions comprising these compounds; and methods of treating a disease, disorder, or condition associated with FXR dysregulation, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.
- -
-
Page/Page column 83
(2020/08/28)
-
- SOLID STATE FORMS OF (2E)-N-HYDROXY-3-[3-(PHENYLSULFAMOYL)PHENYL]PROP-2-ENAMIDE AND PROCESS FOR PREPARATION THEREOF
-
The Present invention relates to solid state forms of (2E)-N-hydroxy-3-[3-(N-phenyl sulfamoyl)phenyl]prop-2-enamide represented by the following structural formula-1 and process for the preparation thereof.
- -
-
Page/Page column 14-15
(2018/03/06)
-
- Synthesis and applications of novel FXR agonists
-
The present invention relates to the field of chemical drugs, and discloses a synthesis strategy of novel FXR agonists such as Fex-3 and Fex-4. According to the present invention, the steps of the synthesis strategy are simple, the total yield is high, th
- -
-
Paragraph 0007; 0013
(2017/04/28)
-
- FARNESOID X RECEPTOR AGONISTS AND USES THEREOF
-
Described herein are compounds that are farnesoid X receptor agonists, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with farnesoid X receptor activity.
- -
-
Paragraph 00393
(2017/04/11)
-
- FARNESOID X RECEPTOR AGONISTS AND USES THEREOF
-
Described herein are compounds that are farnesoid X receptor agonists, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with farnesoid X receptor activity.
- -
-
Paragraph 00408
(2017/04/11)
-
- Pd0.09Ce0.91O2-Δ: A sustainable ionic solid-solution precatalyst for heterogeneous, ligand free Heck coupling reactions
-
A quick and easy method for the preparation of Pd2+ metal ion substituted in ceria, Pd0.09Ce0.91O2-δ solid solution oxide, is described. The Pd0.09Ce0.91O2-δ solid solution oxide was fully characterized by XRD, ICP-OES, BET, XPS, SEM, EDX, TEM, TGA and Raman spectroscopy. All characterization techniques strongly suggested that Pd2+ was successfully incorporated into the lattice structure of ceria. The effect of the reaction conditions on the catalytic properties of the Pd0.09Ce0.91O2-δ solid solution catalyst initially was studied in detail with the model Heck reaction of iodobenzene and methylacrylate to obtain optimum reaction conditions. The Pd0.09Ce0.91O2-δ solid solution catalyst then afforded substituted alkenes in good to excellent yields under these optimum reaction conditions. Steric and electronic effects were also studied, and were found to influence the catalytic activity. Characterization of the used catalyst suggests that Pd2+ in Pd0.09Ce0.91O2-δ is reduced in situ to Pd0 when employed in the Heck cross-coupling reactions. The catalyst was easily recovered by centrifuge and reused three times without significant loss of catalytic efficiency.
- Mpungose, Philani P.,Sehloko, Neo I.,Dasireddy, Venkata D.B.C.,Mahadevaiah, Narayanappa,Maguire, Glenn E.,Friedrich, Holger B.
-
-
- ANALOGS OF FEXARAMINE AND METHODS OF MAKING AND USING
-
Novel compounds having a formula embodiments of a method of making the same, and of a composition comprising them are disclosed herein. Also disclosed are embodiments of a method of treating or preventing a metabolic disorder in a subject, comprising administering to a subject (e.g., via the gastrointestinal tract) a therapeutically effective amount of one or more of the disclosed compounds, thereby activating FXR receptors in the intestines, and treating or preventing a metabolic disorder in the subject. Additionally disclosed are embodiments of a method of treating or preventing inflammation in an intestinal region of a subject, comprising administering to the subject (e.g., via the gastrointestinal tract) a therapeutically effective amount of one or more of the disclosed compounds, thereby activating FXR receptors in the intestines, and thereby treating or preventing inflammation in the intestinal region of the subject.
- -
-
Page/Page column 120; 121
(2015/10/05)
-
- Multifunctional cyclodextrin-based N,N-bidentate ligands for aqueous Heck arylation
-
Novel Pd(II) complexes coordinated by N,N-bidentate ligands derived from cyclodextrins have been synthesized by copper-catalyzed azide alkyne 1,3-cycloaddition (CuAAC). Depending on the nature of the N,N-bidentate ligand, fast or slow equilibriums between the free N,N-bidentate ligand and the Pd-species were detected by NMR measurements. The new Pd(II) complexes acted as efficient water soluble catalysts for the Heck reaction of aryl iodides in aqueous medium. The reaction could tolerate aerobic conditions and affords the coupling products in good yields. Once the reaction was complete, the product and the catalyst could be recovered separately by simple decantation.
- Potier, Jonathan,Menuel, Stéphane,Rousseau, Jolanta,Tumkevicius, Sigitas,Hapiot, Frédéric,Monflier, Eric
-
-
- TREATMENT OF CANCERS HAVING K-RAS MUTATIONS
-
The present invention provides a method of treating a cancer associated with a K-ras mutation in a subject in need thereof. The method comprises the steps of: (1) identifying a subject with a cancer associated with a K-ras mutation; and (2) administering to the subject (i) an inhibitor of PI3 kinase and (ii) an HDAC inhibitor, wherein the PI3 kinase inhibitor and the HDAC inhibitor are administered in amounts which together are therapeutically effective.
- -
-
Paragraph 0625
(2013/05/08)
-
- TREATMENT OF CANCERS HAVING K-RAS MUTATIONS
-
The present invention provides a method of treating a cancer associated with a K- ras mutation in a subject in need thereof. The method comprises the steps of (1) identifying a subject with a cancer associated with a K-ras mutation; and (2) adminsiterign to the subject (i) an inhibitor of PI3 kinase and (ii) an HDAC inhibitor, wherein the PI3 kinase inhibitor and the HDAC inhibitor are administered in amounts which together are therapeutically effective.
- -
-
Page/Page column 238-239
(2011/11/01)
-
- Discovery of inhibitors of aberrant gene transcription from libraries ofdna binding molecules: Inhibition of LEF-1-mediated gene transcription and oncogenic transformation
-
The screening of a >9000 compound library of synthetic DNA binding molecules for selective binding to the consensus sequence of the transcription factor LEF-1 followed by assessment of the candidate compounds in a series of assays that characterized functional activity (disruption of DNA-LEF-1 binding) at the intended target and site (inhibition of intracellular LEF-1-mediated gene transcription) resulting in a desired phenotypic cellular change (inhibit LEF-1-driven cell transformation) provided two lead compounds: lefmycin-1 and lefmycin-2. The sequence of screens defining the approach assures that activity in the final functional assay may be directly related to the inhibition of gene transcription and DNA binding properties of the identified molecules. Central to the implementation of this generalized approach to the discovery of DNA binding small molecule inhibitors of gene transcription was (1) the use of a technically nondemanding fluorescent intercalator displacement (FID) assay for initial assessment of the DNA binding affinity and selectivity of a library of compounds for any sequence of interest, and (2) the technology usedto prepare a sufficiently large library of DNA binding compounds.
- Stover, James S.,Shi, Jin,Jin, Wei,Vogt, Peter K.,Boger, Dale L.
-
supporting information; experimental part
p. 3342 - 3348
(2009/07/30)
-
- Preparation of the central tryptophan moiety of the celogentin/moroidin family of anti-mitotic cyclic peptides
-
The central functionalized tryptophan core of the celogentin/moroidin family of cyclic peptides has been prepared. The strategy incorporates a novel preparation of 4-iodobenzaldehyde and employs a Larock annulation as the key step. CSIRO 2006.
- Yuen, Alexander K. L.,Jolliffe, Katrina A.,Hutton, Craig A.
-
p. 819 - 826
(2007/10/03)
-
- Novel sulfonamide derivatives as inhibitors of histone deacetylase
-
Inhibition of the enzyme histone deacetylase (HDAC) is emerging as a novel approach to the treatment of cancer. A series of novel sulfonamide derivatives were synthesized and evaluated for their ability to inhibit human HDAC. Compounds were identified which are potent enzyme inhibitors, with IC 50 values in the low nanomolar range against enzyme obtained from HeLa cell extracts, and with antiproliferative effects in cell culture. Extensive characterization of the structure - activity relationships of this series identified key requirements for activity. These include the direction of the sulfonamide bond and substitution patterns on the central phenyl ring. The alkyl spacer between the aromatic head group and the sulfonamide functionality also influenced the HDAC inhibitory activity. One of these compounds, m11.1, also designated PXD101, has entered clinical trials for solid tumors and haematological malignancies.
- Finn, Paul W.,Bandara, Morwena,Butcher, Chris,Finn, Angela,Hollinshead, Ruth,Khan, Nagma,Law, Norman,Murthy, Sreenivasa,Romero, Rosario,Watkins, Clare,Andrianov, Victor,Bokaldere, Rasma M.,Dikovska, Klara,Gailite, Vija,Loza, Einars,Piskunova, Irina,Starchenkov, Igor,Vorona, Maxim,Kalvinsh, Ivars
-
p. 1630 - 1657
(2007/10/03)
-
- Selective reduction of nitrocinnamoylfumagillols with α,β- unsaturated ester using Borohydride Exchange Resin (BER) - nickel acetate
-
Borohydride Exchange Resin (BER) - nickel acetate system readily reduces nitrocinnamoylfumagillols to the corresponding amines in excellent yields, high chemoselectivity, and simple procedure. Especially, this system tolerates two epoxides (spiro-epoxide
- Hong, Woo Lee,Joong, Bok Ahn,Jung, Hwa Lee,Sung, Kwon Kang,Soon, Kil Ahn,Sang, Joon Lee
-
p. 1843 - 1856
(2007/10/03)
-
- Carbamic acid compounds comprising a sulfonamide linkage as hdac inhibitors
-
This invention pertains to certain active carbamic acid compounds which inhibit HDAC activity and which have the following formula: (I) A is an aryl group; Q1 is a covalent bond or an aryl leader group; J is a sulfonamide linkage selected from: —S (═O)2NR1— and —NR1S(═O)2—; R1 is a sulfonamido substituent; and, Q2 is an acid leader group; with the proviso that if J is —S(═O)2NR1—, then Q1 is an aryl leader group; and pharmaceutically acceptable salts, solvates, amides, esters, ethers, chemically protected forms, and prodrugs thereof. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit HDAC, and, e.g., to inhibit proliferative conditions, such as cancer and psoriasis.
- -
-
-
- Process for the preparation of unsaturated amino compounds
-
Process for the preparation of aromatic amines which additionally still contain C-C multiple bonds, characterized in that aromatic nitro compounds which still contain C-C multiple bonds are hydrogenated in the presence of metal sulphides of the formula Me
- -
-
-